Context and question: Prior to the second world war, birth control was prohibited in many countries, and in the United States even the discussion of contraceptive methods sometimes led to prosecution under Comstock laws. The history of the development of oral contraceptives is thus closely tied to the birth control movement and the efforts of activists Margaret Sanger, Mary Dennett, and Emma Goldman. Based on fundamental research performed by Gregory Pincus and synthetic methods for progesterone developed by Carl Djerassi at Syntex and by Frank Colton at G.D. Searle & Co., the first oral contraceptive, Enovid, was developed by E.D. Searle and Co. and approved by the FDA in 1960. The original formulation incorporated vastly excessive doses of hormones, and caused severe side effects. Nonetheless, by 1962, 1.2 million American women were on the pill, and by 1965 the number had increased to 6.5 million. The availability of a convenient form of temporary contraceptive led to dramatic changes in social mores including expanding the range of lifestyle options available to women, reducing the reliance of women on men for contraceptive practice, encouraging the delay of marriage, and increasing pre-marital co-habitation.
What was the name of the first oral contraceptive?
Answer: Enovid
Context and question: A Frankish identity emerged and so did their Frankish or Franconian language. The language itself is poorly attested. A notable exception is the Bergakker inscription, found near the Dutch city of Tiel, which may represent a primary record of 5th-century Frankish. Although some placenames recorded in Roman texts could arguably be considered as the oldest "Dutch" single words, like vadam (modern Dutch: wad, English: "mudflat"), the Bergakker inscription yields the oldest evidence of Dutch morphology, but there is no consensus on the interpretation of the rest of the text.
What's another term for "Frankish"?
Answer: Franconian
Context and question: The BCG vaccine has limitations, and research to develop new TB vaccines is ongoing. A number of potential candidates are currently in phase I and II clinical trials. Two main approaches are being used to attempt to improve the efficacy of available vaccines. One approach involves adding a subunit vaccine to BCG, while the other strategy is attempting to create new and better live vaccines. MVA85A, an example of a subunit vaccine, currently in trials in South Africa, is based on a genetically modified vaccinia virus. Vaccines are hoped to play a significant role in treatment of both latent and active disease.
How many main limitations does the BCG vaccine have?
Answer:
unanswerable